Incyte Stock Slumps After Firm Scraps Drug, Pauses Enrollment in Other Study

Investopedia11-20 01:41

KEY TAKEAWAYS Incyte led S&P 500 decliners Tuesday afternoon after the pharmaceutical firm said it will stop developing one drug and pause enrollment in the study of another.Enrollment in the ongoing ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484697654?lang=en_US&edition=fundamental","thumbnail":"https://www.investopedia.com/thmb/k3Dg1Xwh9u7JgXradqtMGg05qEw=/3888x2592/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-1233092220-251e1a4b7a394dce8b4d9a6f2d3cc5c2.jpg","is_english":true,"pubTime":"2024-11-20 01:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484697654","market":"sg","top_or_hot":-1,"title":"Incyte Stock Slumps After Firm Scraps Drug, Pauses Enrollment in Other Study","media":"Investopedia","content":"<div>\n<p>KEY TAKEAWAYS\nIncyte led S&P 500 decliners Tuesday afternoon after the pharmaceutical firm said it will stop developing one drug and pause enrollment in the study of another.Enrollment in the ongoing ...</p>\n\n<a href=\"https://www.investopedia.com/incyte-stock-slumps-after-firm-scraps-drug-pauses-enrollment-in-other-study-8747876\">Source Link</a>\n\n</div>\n","source":"investopedia_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Incyte Stock Slumps After Firm Scraps Drug, Pauses Enrollment in Other Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIncyte Stock Slumps After Firm Scraps Drug, Pauses Enrollment in Other Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-20 01:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investopedia.com/incyte-stock-slumps-after-firm-scraps-drug-pauses-enrollment-in-other-study-8747876><strong>Investopedia</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY TAKEAWAYS\nIncyte led S&P 500 decliners Tuesday afternoon after the pharmaceutical firm said it will stop developing one drug and pause enrollment in the study of another.Enrollment in the ongoing ...</p>\n\n<a href=\"https://www.investopedia.com/incyte-stock-slumps-after-firm-scraps-drug-pauses-enrollment-in-other-study-8747876\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.investopedia.com/incyte-stock-slumps-after-firm-scraps-drug-pauses-enrollment-in-other-study-8747876","article_id":"2484697654","we_media_id":null,"thumbnails":["https://www.investopedia.com/thmb/k3Dg1Xwh9u7JgXradqtMGg05qEw=/3888x2592/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-1233092220-251e1a4b7a394dce8b4d9a6f2d3cc5c2.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484697654","pubTimestamp":1732038060,"sourceInfo":{"source_id":"investopedia_highlight","name":"Investopedia"},"weMediaInfo":null,"summary":"Incyte led S&P 500 decliners Tuesday afternoon after the pharmaceutical firm said it will stop developing one drug and pause enrollment in the study of another.Enrollment in the ongoing Phase 2 trial of a drug to treat chronic spontaneous urticaria , or chronic hives, was paused.The biopharmaceutical firm also said it won't develop the drug to treat cholestatic pruritus , a liver disorder that causes intense itching.Incyte  led S&P 500 decliners Tuesday afternoon after the pharmaceutical firm said it will stop developing one drug and pause enrollment in the study of another.Enrollment in the ongoing Phase 2 trial of MRGPRX2  in chronic spontaneous urticaria , or chronic hives, was paused \"following the observation of certain in vivo preclinical toxicology findings.\". Incyte Says It Won't Develop Drug To Treat Intense Itching. It also said data from the Phase 2 study of MRGPRX4  to treat cholestatic pruritus , a liver disorder that causes intense itching, \"does not support further devel","collect":0,"end_time":0,"defaultTopTitle":"investopedia.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4550":"红杉资本持仓","INCY":"因塞特医疗","CP":"加拿大太平洋铁路","BK4532":"文艺复兴科技持仓","BK4016":"铁路","LU1261432733.SGD":"Fidelity World A-ACC-SGD","BK4139":"生物科技","BK4585":"ETF&股票定投概念"},"translate_title":"Incyte公司放弃药物并暂停其他研究招募后股价暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CP":1,"INCY":1},"content_text":"KEY TAKEAWAYS\nIncyte led S&P 500 decliners Tuesday afternoon after the pharmaceutical firm said it will stop developing one drug and pause enrollment in the study of another.Enrollment in the ongoing Phase 2 trial of a drug to treat chronic spontaneous urticaria (CSU), or chronic hives, was paused.The biopharmaceutical firm also said it won't develop the drug to treat cholestatic pruritus (CP), a liver disorder that causes intense itching.\n Incyte (INCY) led S&P 500 decliners Tuesday afternoon after the pharmaceutical firm said it will stop developing one drug and pause enrollment in the study of another.\n\n\n Enrollment in the ongoing Phase 2 trial of MRGPRX2 (INCB000262) in chronic spontaneous urticaria (CSU), or chronic hives, was paused \"following the observation of certain in vivo preclinical toxicology findings.\"\n\n\n In vivo toxicology is the study of the effect of the toxicity of a drug on a live organism, usually an animal.\n\n\n  Incyte Says It Won't Develop Drug To Treat Intense Itching  \n It also said data from the Phase 2 study of MRGPRX4 (INCB000547) to treat cholestatic pruritus (CP), a liver disorder that causes intense itching, \"does not support further development.\"\n\n\n Incyte said it had shared the data with the Food and Drug Administration (FDA) and will work with the agency to \"determine next steps.\"\n\n\n The company's stock recently was down more than 13%. It is up about 6% this year.\n\nDo you have a news tip for Investopedia reporters? Please email us at\ntips@investopedia.com","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484697654"}